• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Hepregen

edit

Hepregen Corporation is pursuing applications of its microliver platform for acute and chronic toxicity as well as for understanding the metabolism of drugs in the liver. Applications in the pharmaceutical industry may well extend beyond toxicity and metabolism to include utility in drug discovery, disease modeling (obesity, infectious disease, diabetes), in silico models, and toxicogenomics. Hepregen is actively engaged in industrial collaborations to validate the microliver platform in a wide spectrum of applications. The combined markets for Hepregen’s microliver platform is approximately a billion dollars annually.

Recent Milestones

edit

• 
  Hepregen received $500k in Grant funding. (6/27/12)
  Posted 6/27/12 at 5:44pm via masshightech.com
• 
  Hepregen received $500k in Grant funding. (5/25/11)
  Posted 5/25/11 at 5:06pm via masshightech.com
• 
  Hepregen received $500k in Grant funding. (1/15/10)
  Posted 1/19/10 at 9:45pm via venturebeat.com
• 
  Hepregen received $3M in Series A funding. (9/2/08)
  Posted 6/21/09 at 8:23pm via xconomy.com
• 
  Hepregen added Bernadette C. Fendrock as President and CEO.
  Posted 6/21/09 at 8:11pm
• 
  Hepregen added Salman Khetani as Director, Research.
  Posted 6/21/09 at 8:11pm

Videos

Screenshots

edit

Above: Hepregen
Uploaded: 6/22/09

Sources

1. Hepregen Raises $3 Million To Screen Drugs for Liver Damage (xconomy.com) [edit]
2. Click here to find out more! Hepregen lands $500K SBIR grant for liver drug testing (deals.venturebeat.com) [edit]
3. Mass. Life Sciences Center awards $2M in matching grants (masshightech.com) [edit]
4. Hepregen gets $500K grant (masshightech.com) [edit]